GHS Peptides
Tesamorelin
Research Grade≥99% PurityLyophilized
A GHRH analog investigated for its receptor binding profile and GH secretion pathway research.
Dosage
$85.00
Quantity
Bundle & Save
We accept
Certificate of Analysis
Third Party Tested by Freedom Diagnostics
Frequently Bought Together
Bacteriostatic Water
10 ml
$10.00
GLP-3 RT
10 mg
$110.00
GLP-2 TZ
10 mg
$85.00
NAD+
500 mg
$70.00
GHK-Cu
50 mg
$65.00
BPC-157
5 mg
$45.00
Melanotan II
10 mg
$55.00
TB-500
10 mg
$45.00
MOTS-c
10 mg
$75.00
Research Summary
Tesamorelin
Published research data and clinical observations
🔬
Research Phase
Extensive clinical data available
💉
Administration
Subcutaneous, daily
🧬
Key Mechanism
Trans-3-hexenoic acid modified
📄
Publications
Including Phase III RCTs
👥
Phase III Subjects
LIPO-010/011 pooled trials
What Makes Tesamorelin Different?
The Science, Simplified
Signal the Pituitary, Not Replace GH
Tesamorelin doesn't inject growth hormone directly — it tells your pituitary to release it naturally. This preserves the body's own pulsatile rhythm and feedback loops, avoiding the risks of supraphysiological GH levels.
GHRH
Primary
GHRH Receptor
Pituitary somatotrophs
Stimulates GH release
Preserved pulsatility
Clinically validated mechanism
GH
Output
Growth Hormone
Pulsatile release pattern
Visceral fat reduction
Hepatic fat oxidation
Maintains feedback loops
IGF-1
Downstream
Insulin-like Growth Factor
Liver-produced mediator
Tissue growth signaling
Metabolic regulation
Dose-dependent increase
WHY PULSATILITY MATTERS
Natural Rhythm, Not a Flood
Direct GH injection creates flat, supraphysiological levels. Tesamorelin stimulates natural GH pulses — and the body can still regulate itself:
Reduced visceral fat 18% while preserving subcutaneous fat — a selectivity impossible with exogenous GH injection.
TesamorelinPulsatile GH (clinically validated)
HGH injectionFlat supraphysiological levels
SermorelinPulsatile but shorter t½
What Researchers Observed
-18%
Visceral fat reduction at 26 weeks
Falutz et al. (2010) pooled Phase III, n=806
72%
82%
65%
45%
Key Milestones Achieved
82%
Extension study confirmation
75%
Dose-dependent, physiological range
68%
-37% relative, Stanley et al. 2014
For context:Tesamorelin (Egrifta) was approved in 2010 for HIV-associated lipodystrophy based on two Phase III RCTs (LIPO-010/011). Pooled analysis (Falutz et al. 2010, n=806, 2:1 randomization) showed VAT decreased -10.9% (-21 cm2) vs -0.6% (-1 cm2) placebo over 26 weeks, with sustained reduction at 52 weeks.
Compound Information
Technical specifications
❄️ Storage Requirements
Stability Information
Avoid freeze/thaw cyclesProtect from lightKeep refrigerated
Lyophilized (powder)
-20°C · 24+ months
Reconstituted
2-8°C · ~30 days
📋 Development Status
Where It Stands
Extensively StudiedResearch Use Only
DeveloperTheratechnologies
Trial ProgramLIPO-010/011
ResultsPhase III trials completed (Egrifta)
This page summarizes published research for informational purposes only. These products are sold exclusively as research chemicals and are not intended for human consumption. Always consult peer-reviewed literature for complete study details.
Your Cart
Your cart is empty